Mirum Pharmaceuticals, Inc.

NYSE/NASDAQ:MIRMPharma

San Diego, California, United States · Est. 2014

Mirum Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for liver and bile duct diseases.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

7 drugs in development

Approved1

Phase 33

Phase 24

Preclinical1

By Therapeutic Area

top 2

Infectious Disease

333%

Gastroenterology

111%

R&D Momentum

45/100

Pipeline Velocity

22/100

Trial Completion Rate

83/100

Pipeline Concentration

43/100

Pipeline Freshness

74/100

Strategic Signals

↗Active in Gastroenterology but thin pipeline — potential licensing opportunity

Activity

Key Events

Jun 30, 2026TrialA Randomized, Open-label, Multicenter, Phase 3 Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

Jun 30, 2026TrialA Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)

Jun 24, 2026TrialAn Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)

Jun 24, 2026TrialLong-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)

Jan 26, 20268-KMirum Pharmaceuticals, Inc. (MIRM) (CIK 0001759425)

Nov 22, 2025TrialStudy of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)

Aug 27, 2025TrialA Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

Apr 10, 2025FDALivmarli — LIVMARLI

4 more events

Mar 25, 2025TrialA Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection

Oct 14, 2024TrialEvaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

Sep 21, 2023TrialLong-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)

Sep 29, 2021FDALivmarli — LIVMARLI

Details

Company Info

Company Overview

—

Mkt Cap

$186.4M

Revenue

$222.5M

Cash

CEONiall Booker

Founded2014

HQSan Diego, California, United States

ExchangeNYSE/NASDAQ:MIRM

Therapeutic Focus

Metabolic & EndocrineOtherGastroenterologyDermatologyInfectious Disease

Patent Expirations

4 patent groups across drugs · Source: FDA Orange Book

DrugExpires

LivmarliMay 26, 2031 Livmarli4 patentsOct 26, 2032 Livmarli4 patentsFeb 12, 2040 LivmarliOct 5, 2043

Recent SEC Filings

8-KJan 26, 2026

Mirum Pharmaceuticals, Inc. (MIRM) (CIK 0001759425)

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

BrelovitugPreclinical

Chronic Hepatitis D Infection

BrelovitugPhase 3

Delayed Treatment with BrelovitugPhase 3

Unknown / Other

Alagille Syndrome

LivmarliApproved

Fragile X Syndrome

High dose of MRM-3379Phase 2

Low dose of MRM-3379Phase 2

Middle Dose of MRM-3379Phase 2

Intrahepatic Cholestasis

VolixibatPhase 2

Regulatory

Regulatory Timeline

20151 event

FDAMar 17

Cholbam — CHOLBAM

Application NDA205750 (NDA)

20211 event

FDASep 29

Livmarli — LIVMARLI

Application NDA214662 (NDA)

20251 event

FDAApr 10

Livmarli — LIVMARLI

Application NDA219485 (NDA)

20261 event

SECJan 26

Mirum Pharmaceuticals, Inc. (MIRM) (CIK 0001759425)

Accession: 001-38981

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)